ClinicalTrials.gg
CompletedNCT01191268Updated Oct 8, 2014Results posted

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

A Phase 3 interventional study of Insulin Glargine and LY2189265 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 101 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-08.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
884
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
5th of 54
884 · median 159
Started
2010
with 6 others
Phase 3
22 of 54
1 open now
Registered
9th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 7 that started in 2010, is one of 22 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.

Read the detailed description

The term rescue therapy in this trial was defined as therapy for participants who met criteria for persistent severe hyperglycemia and therapy for participants who required new intervention for any other reason. The latter included participants who discontinued study drug due to adverse events, participant decision, or any other reason. For efficacy analyses, participants who received rescue medication were included in the analysis population, but only measurements obtained prior to taking rescue therapy were included in the efficacy analysis. For safety analyses, with the exception of hypoglycemia, all measurements including those obtained after taking rescue therapy were included in the analysis.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Currently using insulin for at least 3 months with a conventional insulin regimen with or without oral medications
  • Glycosylated () greater than or equal to 7% and less than or equal to 11%
  • Willing to inject subcutaneous medication
  • Willing to monitor blood glucose levels and adjust insulin dose
  • Willing to maintain a study diary
  • (BMI) between 23 and 45 kilograms per square meter (kg/m\^2)
  • Stable weight for 3 months prior to screening
  • Females of child bearing potential must test negative for pregnancy at screening and be willing to use a reliable method of during the study and for 1 month following the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes
  • Previous therapy with glucagon-like peptide 1 (GLP-1) agonists within 3 months prior to screening
  • 1 or more episodes of ketoacidosis within 6 months prior to screening
  • Have been treated with prescription or over the counter medication to promote weight loss within 3 months prior to screening
  • Estimated (eGFR) less than or equal to 30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) at screening
  • Taking for greater than 14 days except for topical, eye, nasal, or inhaled
  • History of heart failure, New York Heart Classification III or IV within 2 months prior to screening
  • Gastrointestinal (GI) problems such as diabetic gastroparesis or bariatric surgery (stomach stapling) or chronically taking medications that directly affect GI motility
  • Acute or chronic hepatitis or pancreatitis
  • Self or family history of 2A or type 2B multiple endocrine neoplasia or medullary C-Cell hyperplasia
  • Serum calcitonin greater than or equal to 20 picograms per milliliter (pcg/mL) at screening
  • Organ transplant except cornea
  • Significant active disease such as Lupus or Rheumatoid Arthritis
  • History of or active except skin or in situ cervical or prostate cancer within the last 5 years
  • Known drug or alcohol abuse
  • Have enrolled in another clinical trial within the last 30 days
  • Have previously signed an or participated in a LY2189265 study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
884 participants (actual)

Study arms

  • Experimental
    1.5 mg LY2189265

    LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks

    Drug: LY2189265 · Drug: Insulin Lispro

  • Experimental
    0.75 mg LY2189265

    LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks

    Drug: LY2189265 · Drug: Insulin Lispro

  • Active comparator
    Insulin Glargine

    Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks

    Drug: Insulin Glargine · Drug: Insulin Lispro

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.

    Time frame: Baseline, 26 weeks

Secondary outcomes

  1. Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.

    Time frame: Baseline, 52 weeks

  2. Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52

    The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.

    Time frame: 26 weeks and 52 weeks

  3. Change From Baseline to 26 and 52 Weeks in the Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% Without Nocturnal or Severe Hypoglycemia

    The percentage of participants achieving HbA1c less than 7.0% without nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking) or severe (episodes requiring the assistance of another person to actively administer resuscitative actions) hypoglycemia was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.

    Time frame: Baseline, 26 weeks, and 52 weeks

  4. Change From Baseline to 26 and 52 Weeks in Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles

    The self-monitored plasma glucose (SMPG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. The mean of the 8 time points (Daily Mean) was also calculated. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, metformin, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  5. Change From Baseline to 26 and 52 Weeks in Fasting Serum Glucose

    Fasting serum glucose was measured by the central laboratory. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline fasting blood glucose as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  6. Total Daily Insulin Dose Overall and by Components (Insulin Lispro and Insulin Glargine)

    Total daily insulin (TDI) dose was reported at baseline, 26 weeks, and 52 weeks. Daily Insulin Lispro and Insulin Glargine doses were reported at 26 and 52 weeks.

    Time frame: Baseline and 26 weeks and 52 weeks

  7. Change From Baseline to 26 and 52 Weeks in Body Weight

    Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline body weight as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  8. Body Weight at Baseline, 52 Weeks, and 4 Weeks After Last Dose

    Time frame: Baseline and 52 weeks and 4 weeks after last dose

  9. Change From Baseline to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose in Body Mass Index (BMI)

    Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline BMI as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  10. Change From Baseline to 26 and 52 Weeks in the EQ-5D

    The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, metformin use, and baseline.

    Time frame: Baseline, 26 weeks, and 52 weeks

  11. Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL)

    The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire \[APPADL\]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  12. Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP)

    The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  13. Change From Baseline to 26 and 52 Weeks in the Low Blood Sugar Survey (LBSS)

    The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment and metformin use as fixed effects and baseline score as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  14. Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes

    Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured.

    Time frame: Baseline, 26 weeks, and 52 weeks

  15. Pancreatic Enzymes at Baseline, 52 Weeks, and 4 Weeks After Last Dose

    Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured at baseline and at 4 weeks after last dose (ALD).

    Time frame: Baseline and 52 weeks and 4 weeks after last dose

  16. Change From Baseline to 26 and 52 Weeks in Serum Calcitonin

    Time frame: Baseline, 26 weeks, and 52 weeks

  17. Serum Calcitonin at Baseline, 52 Weeks, and 4 Weeks After Last Dose

    Time frame: Baseline and 52 weeks and 4 weeks after last dose

  18. Change From Baseline to 26 and 52 Weeks in Blood Pressure

    Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline blood pressure as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  19. Blood Pressure at Baseline, 52 Weeks, and 4 Weeks After Last Dose

    Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured.

    Time frame: Baseline and 52 weeks and 4 weeks after last dose

  20. Change From Baseline to 26 and 52 Weeks in Pulse Rate

    Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline as a covariate

    Time frame: Baseline, 26 weeks, and 52 weeks

  21. Pulse Rate at Baseline, 52 Weeks, and 4 Weeks After Last Dose

    Seated pulse rate was measured.

    Time frame: Baseline and 52 weeks and 4 weeks after last dose

  22. Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  23. Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate

    Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.

    Time frame: Baseline, 26 weeks, and 52 weeks

  24. Number of Events of Adjudicated Pancreatitis up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose

    The number of adjudicated (by an independent Clinical Endpoint Committee \[CEC\]) pancreatic events is summarized at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  25. Number of Participants With Self-reported Hypoglycemic Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose

    Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose \[PG\] of ≤ 70 milligrams per deciliter \[mg/dL\]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The number of participants with self-reported hypoglycemic events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks and 52 weeks

  26. Rate of Self-reported Hypoglycemic Events up to 52 Weeks

    Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose \[PG\] of ≤ 70 milligrams per deciliter \[mg/dL\]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  27. Number of Participants With Adjudicated Cardiovascular Events up to 52 Weeks

    Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  28. Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose

    A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

    Time frame: Baseline through 4 weeks after last dose

  29. Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose

    A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks, 52 weeks, and 4 weeks after last dose. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks, 52 weeks, and 4 weeks after last dose

07

Results

Posted Oct 8, 2014

Participant flow

Participant flow — Overall Study
Milestone1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Started295293296
Received at least one dose of study drug295293296
Completed237238244
Not completed585552
Withdrew: Withdrawal by subject192521
Withdrew: Adverse event21138
Withdrew: Physician decision689
Withdrew: Lost to follow-up859
Withdrew: Entry criteria not met311
Withdrew: Death013
Withdrew: Protocol violation101
Withdrew: Sponsor decision020

Outcome measures

PrimaryChange From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobin1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)-1.64 ± 0.07-1.59 ± 0.07-1.41 ± 0.07
Statistical analysis
  • 1.5 mg LY2189265 vs Insulin Glargine · ANCOVA · p = <0.001 (Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.) · Ls mean difference: -0.22 · 95% CI -0.38 to -0.07
  • 0.75 mg LY2189265 vs Insulin Glargine · ANCOVA · p = <0.001 (Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.) · Ls mean difference: -0.17 · 95% CI -0.33 to -0.02
  • 1.5 mg LY2189265 vs Insulin Glargine · ANCOVA · p = 0.005 (Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.) · Ls mean difference: -0.22 · 95% CI -0.38 to -0.07
  • 0.75 mg LY2189265 vs Insulin Glargine · ANCOVA · p = 0.015 (Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.) · Ls mean difference: -0.17 · 95% CI -0.33 to -0.02
SecondaryChange From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobin1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)-1.48 ± 0.08-1.42 ± 0.08-1.23 ± 0.08
Statistical analysis
  • 1.5 mg LY2189265 vs Insulin Glargine · ANCOVA · p = <0.001 (Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.) · Ls mean difference: -0.25 · 95% CI -0.42 to -0.07
  • 0.75 mg LY2189265 vs Insulin Glargine · ANCOVA · p = <0.001 (Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.) · Ls mean difference: -0.19 · 95% CI -0.37 to -0.02
  • 1.5 mg LY2189265 vs Insulin Glargine · ANCOVA · p = 0.005 (Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.) · Ls mean difference: -0.25 · 95% CI -0.42 to -0.07
  • 0.75 mg LY2189265 vs Insulin Glargine · ANCOVA · p = 0.014 (Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.) · Ls mean difference: -0.19 · 95% CI -0.37 to -0.02
SecondaryPercentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52

The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.

Time frame:
26 weeks and 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52
percentage of participants1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
HbA1c less than 7.0%, 26 weeks67.669.056.8
HbA1c less than 7.0%, 52 weeks58.556.349.3
HbA1c less than or equal to 6.5%, 26 weeks48.043.037.5
HbA1c less than or equal to 6.5%, 52 weeks36.734.730.4
Statistical analysis
  • 1.5 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = 0.014 (Treatment comparison for HbA1c less than 7.0% at 26 weeks.)
  • 0.75 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = 0.010 (Treatment comparison for HbA1c less than 7.0% at 26 weeks.)
  • 1.5 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = 0.027 (Treatment comparison for HbA1c less than or equal to 6.5% at 26 weeks.)
  • 0.75 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = 0.384 (Treatment comparison for HbA1c less than or equal to 6.5% at 26 weeks.)
  • 1.5 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = <0.05 (Treatment comparison for HbA1c less than 7% at 52 weeks.)
  • 0.75 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = 0.250 (Treatment comparison for HbA1c less than 7% at 52 weeks.)
  • 1.5 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = 0.272 (Treatment comparison for HbA1c less than or equal to 6.5% at 52 weeks.)
  • 0.75 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = 0.623 (Treatment comparison for HbA1c less than or equal to 6.5% at 52 weeks.)
SecondaryChange From Baseline to 26 and 52 Weeks in the Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% Without Nocturnal or Severe Hypoglycemia

The percentage of participants achieving HbA1c less than 7.0% without nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking) or severe (episodes requiring the assistance of another person to actively administer resuscitative actions) hypoglycemia was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Number · percentage of participants
Change From Baseline to 26 and 52 Weeks in the Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% Without Nocturnal or Severe Hypoglycemia
percentage of participants1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks53.854.528.2
52 weeks44.044.026.8
Statistical analysis
  • 1.5 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 26 weeks.)
  • 0.75 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 26 weeks.)
  • 1.5 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 52 weeks.)
  • 0.75 mg LY2189265 vs Insulin Glargine · Regression, Logistic · p = <0.001 (Treatment comparison at 52 weeks.)
SecondaryChange From Baseline to 26 and 52 Weeks in Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles

The self-monitored plasma glucose (SMPG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. The mean of the 8 time points (Daily Mean) was also calculated. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, metformin, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)]
Change From Baseline to 26 and 52 Weeks in Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles
millimoles per liter (mmol/L)]1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Pre-morning meal, 26 weeks (n=228, 231, 232)-0.36 ± 0.14-0.06 ± 0.14-2.01 ± 0.14
Post-morning meal, 26 weeks (n=220, 227, 229)-3.70 ± 0.19-3.29 ± 0.19-4.03 ± 0.18
Pre-midday meal, 26 weeks (n=227, 231, 233)-2.80 ± 0.16-2.38 ± 0.16-2.65 ± 0.16
Post-midday meal, 26 weeks (n=219, 227, 228)-4.51 ± 0.17-4.53 ± 0.17-3.70 ± 0.17
Pre-evening meal, 26 weeks (n=226, 231, 232)-3.24 ± 0.16-3.06 ± 0.16-2.74 ± 0.16
Post-evening meal, 26 weeks (n=220, 228, 227)-4.61 ± 0.17-4.54 ± 0.17-3.90 ± 0.17
Bedtime, 26 weeks (n=220, 221, 226)-4.00 ± 0.17-3.89 ± 0.17-3.40 ± 0.17
After bedtime, 26 weeks (n=208, 216, 208)-1.48 ± 0.15-1.50 ± 0.15-1.96 ± 0.15
Daily Mean, 26 weeks (n=202, 206, 199)-3.17 ± 0.12-2.97 ± 0.12-3.10 ± 0.12
Pre-morning meal, 52 weeks (n=207, 213, 218)0.03 ± 0.160.05 ± 0.15-2.02 ± 0.15
Post-morning meal, 52 weeks (n=200, 211, 211)-3.38 ± 0.19-3.23 ± 0.19-3.76 ± 0.19
Pre-midday meal, 52 weeks (n=207, 213, 218)-2.53 ± 0.14-2.52 ± 0.14-2.63 ± 0.14
Post-midday meal, 52 weeks (n=202, 210, 212)-4.33 ± 0.18-4.29 ± 0.18-3.83 ± 0.18
Pre-evening meal, 52 weeks (n=207, 214, 217)3.00 ± 0.16-3.07 ± 0.16-2.67 ± 0.16
Post-evening meal, 52 weeks (n=200, 210, 212)-4.22 ± 0.17-4.54 ± 0.17-3.71 ± 0.16
Bedtime, 52 weeks (n=195, 205, 213)-3.62 ± 0.17-3.96 ± 0.17-3.27 ± 0.17
After bedtime, 52 weeks (n=192, 192 197)-1.17 ± 0.15-1.36 ± 0.15-1.80 ± 0.15
Daily Mean, 52 weeks (n=182, 185, 189)-2.84 ± 0.12-2.95 ± 0.12-2.97 ± 0.12
Statistical analysis
  • 1.5 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = 0.628 (Treatment comparison of Daily Mean values at 26 weeks.) · Ls mean difference: -0.07 · 95% CI -0.35 to 0.21
  • 0.75 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = 0.368 (Treatment comparison of Daily Mean values at 26 weeks.) · Ls mean difference: 0.13 · 95% CI -0.15 to 0.41
  • 1.5 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = 0.370 (Treatment comparison of Daily Mean values at 52 weeks.) · Ls mean difference: 0.13 · 95% CI -0.16 to 0.42
  • 0.75 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = 0.879 (Treatment comparison of Daily Mean values at 52 weeks.) · Ls mean difference: 0.02 · 95% CI -0.26 to 0.30
SecondaryChange From Baseline to 26 and 52 Weeks in Fasting Serum Glucose

Fasting serum glucose was measured by the central laboratory. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline fasting blood glucose as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline to 26 and 52 Weeks in Fasting Serum Glucose
millimoles per liter (mmol/L)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks (n=253, 256, 255)-0.27 ± 0.200.22 ± 0.20-1.58 ± 0.20
52 weeks (n=237, 238, 246)0.08 ± 0.220.41 ± 0.22-1.01 ± 0.22
Statistical analysis
  • 1.5 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Treatment comparison at 26 weeks.) · Ls mean difference: 1.31 · 95% CI 0.83 to 1.79
  • 0.75 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Treatment comparison at 26 weeks.) · Ls mean difference: 1.80 · 95% CI 1.32 to 2.28
  • 1.5 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Treatment comparison at 52 weeks.) · Ls mean difference: 1.09 · 95% CI 0.55 to 1.64
  • 0.75 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Treatment comparison at 52 weeks.) · Ls mean difference: 1.42 · 95% CI 0.88 to 1.96
SecondaryTotal Daily Insulin Dose Overall and by Components (Insulin Lispro and Insulin Glargine)

Total daily insulin (TDI) dose was reported at baseline, 26 weeks, and 52 weeks. Daily Insulin Lispro and Insulin Glargine doses were reported at 26 and 52 weeks.

Time frame:
Baseline and 26 weeks and 52 weeks
Reported as:
Mean · units
Total Daily Insulin Dose Overall and by Components (Insulin Lispro and Insulin Glargine)
units1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
TDI, Baseline55.20 ± 32.1759.11 ± 38.1253.93 ± 30.67
TDI, 26 weeks (n=244, 251, 254)93.24 ± 78.0296.69 ± 62.13132.00 ± 79.01
TDI, 52 weeks (n=224, 227, 238)88.15 ± 62.9595.00 ± 67.62133.19 ± 80.75
Insulin Lispro, 26 weeks (n=244, 251, 254)93.24 ± 78.0296.69 ± 62.1367.79 ± 44.59
Insulin Lispro, 52 weeks (n=224, 227, 238)88.15 ± 62.9595.00 ± 67.6269.12 ± 49.07
Insulin Glargine, 26 weeks (n=244, 251, 254)NA ± NANA ± NA64.48 ± 40.23
Insulin Glargine, 52 weeks (n=224, 227, 238)NA ± NANA ± NA64.07 ± 38.60
SecondaryChange From Baseline to 26 and 52 Weeks in Body Weight

Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline body weight as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline to 26 and 52 Weeks in Body Weight
kilograms (kg)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks-0.87 ± 0.270.18 ± 0.272.33 ± 0.27
52 weeks-0.35 ± 0.340.86 ± 0.332.89 ± 0.33
Statistical analysis
  • 1.5 mg LY2189265 vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 26 weeks.) · Ls mean difference: -3.20 · 95% CI -3.81 to -2.59
  • 0.75 mg LY2189265 vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 26 weeks.) · Ls mean difference: -2.15 · 95% CI -2.76 to -1.54
  • 1.5 mg LY2189265 vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 52 weeks.) · Ls mean difference: -3.23 · 95% CI -3.99 to -2.48
  • 0.75 mg LY2189265 vs Insulin Glargine · ANCOVA · p = <0.001 (Treatment comparison at 52 weeks.) · Ls mean difference: -2.03 · 95% CI -2.78 to -1.27
SecondaryBody Weight at Baseline, 52 Weeks, and 4 Weeks After Last Dose
Time frame:
Baseline and 52 weeks and 4 weeks after last dose
Reported as:
Mean · kilograms (kg)
Body Weight at Baseline, 52 Weeks, and 4 Weeks After Last Dose
kilograms (kg)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Baseline91.00 ± 18.2491.69 ± 18.0390.75 ± 18.87
52 weeks (n=290, 290, 295)91.58 ± 19.0693.21 ± 19.2394.14 ± 19.72
4 weeks after last dose (n=259, 260, 253)91.69 ± 18.6093.14 ± 19.2094.27 ± 20.13
SecondaryChange From Baseline to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose in Body Mass Index (BMI)

Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline BMI as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · kilograms per meter squared (kg/m^2)
Change From Baseline to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose in Body Mass Index (BMI)
kilograms per meter squared (kg/m^2)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks (n=248, 251, 250)-0.20 ± 0.090.21 ± 0.091.01 ± 0.09
52 weeks (n=225, 224, 232)0.09 ± 0.110.57 ± 0.111.33 ± 0.11
4 weeks after last doseNA ± NANA ± NANA ± NA
Statistical analysis
  • 1.5 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Treatment comparison at 26 weeks.) · Ls mean difference: -1.20 · 95% CI -1.44 to -0.96
  • 0.75 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Treatment comparison at 26 weeks.) · Ls mean difference: -0.79 · 95% CI -1.03 to -0.55
  • 1.5 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Treatment comparison at 52 weeks.) · Ls mean difference: -1.24 · 95% CI -1.55 to -0.94
  • 0.75 mg LY2189265 vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Treatment comparison at 52 weeks.) · Ls mean difference: -0.76 · 95% CI -1.06 to -0.46
SecondaryChange From Baseline to 26 and 52 Weeks in the EQ-5D

The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, metformin use, and baseline.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 and 52 Weeks in the EQ-5D
units on a scale1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
EQ-5D UK, 26 weeks (n=272, 271, 274)-0.03 ± 0.01-0.03 ± 0.01-0.03 ± 0.01
EQ-5D UK, 52 weeks (n=274, 274, 281)-0.04 ± 0.01-0.04 ± 0.01-0.03 ± 0.01
VAS, 26 weeks (n=278, 275, 275)-1.69 ± 1.00-2.30 ± 1.00-0.60 ± 1.00
VAS, 52 weeks (n=279, 278, 282)-0.46 ± 1.01-2.54 ± 1.02-0.18 ± 1.01
SecondaryChange From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL)

The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire \[APPADL\]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL)
units on a scale1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks (n=274, 270, 270)-0.50 ± 0.30-0.60 ± 0.31-0.93 ± 0.31
52 weeks (n=277, 275, 279)-0.50 ± 0.33-1.05 ± 0.33-1.28 ± 0.33
SecondaryChange From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP)

The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP)
units on a scale1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks (n=277, 274, 274)0.60 ± 0.170.34 ± 0.170.18 ± 0.17
52 weeks (n=278, 277, 281)0.86 ± 0.160.22 ± 0.160.06 ± 0.16
SecondaryChange From Baseline to 26 and 52 Weeks in the Low Blood Sugar Survey (LBSS)

The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment and metformin use as fixed effects and baseline score as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 26 and 52 Weeks in the Low Blood Sugar Survey (LBSS)
units on a scale1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks (n=251, 256, 250)3.75 ± 1.312.91 ± 1.292.83 ± 1.30
52 weeks (n=234, 238, 244)2.51 ± 1.250.92 ± 1.232.38 ± 1.23
SecondaryChange From Baseline to 26 and 52 Weeks in Pancreatic Enzymes

Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Median · units per liter (U/L)
Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes
units per liter (U/L)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Amylase (total), 26 weeks (n=284, 282, 287)5.00 (-2.00 to 15.00)4.00 (-1.00 to 10.00)1.00 (-4.00 to 8.00)
Amylase (total), 52 weeks (n=284, 283, 287)2.00 (-3.00 to 12.00)2.00 (-4.00 to 9.00)0.00 (-7.00 to 6.00)
Amylase (PD), 26 weeks (n=284, 282, 287)4.00 (0.00 to 10.00)2.50 (0.00 to 7.00)1.00 (-2.00 to 4.00)
Amylase (PD), 52 weeks (n=284, 283, 287)3.00 (-2.00 to 9.00)2.00 (-2.00 to 5.00)0.00 (-3.00 to 3.00)
Lipase, 26 weeks (n=284, 282, 287)7.00 (0.00 to 17.00)4.00 (-3.00 to 12.00)-2.00 (-8.00 to 3.00)
Lipase, 52 weeks (n=284, 283, 287)6.00 (-1.00 to 16.50)3.00 (-3.00 to 11.00)-2.00 (-9.00 to 4.00)
SecondaryPancreatic Enzymes at Baseline, 52 Weeks, and 4 Weeks After Last Dose

Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured at baseline and at 4 weeks after last dose (ALD).

Time frame:
Baseline and 52 weeks and 4 weeks after last dose
Reported as:
Mean · units per liter (U/L)
Pancreatic Enzymes at Baseline, 52 Weeks, and 4 Weeks After Last Dose
units per liter (U/L)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Amylase (total), Baseline61.21 ± 27.8958.59 ± 23.1961.18 ± 26.69
Amylase (total), 52 weeks (n=284, 283, 287)66.08 ± 30.2960.97 ± 25.7861.93 ± 27.12
Amylase (total), 4 weeks ALD (n=251, 259, 251)61.69 ± 28.0659.21 ± 30.3262.13 ± 26.11
Amylase (PD), Baseline26.56 ± 14.5125.10 ± 13.4826.43 ± 15.94
Amylase (PD), 52 weeks (n=284, 283, 287)31.38 ± 18.1527.86 ± 17.1426.91 ± 17.64
Amylase (PD), 4 weeks ALD (n=251, 260, 251)27.50 ± 15.4925.77 ± 13.7826.84 ± 15.44
Lipase, Baseline41.42 ± 34.1941.08 ± 32.8043.20 ± 37.35
Lipase, 52 weeks (n=284, 283, 287)50.57 ± 35.6545.34 ± 31.2339.39 ± 27.51
Lipase, 4 weeks ALD (n=252, 260, 251)44.19 ± 36.9241.86 ± 25.2243.02 ± 35.75
SecondaryChange From Baseline to 26 and 52 Weeks in Serum Calcitonin
Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Median · picogram per milliliter (pcg/mL)
Change From Baseline to 26 and 52 Weeks in Serum Calcitonin
picogram per milliliter (pcg/mL)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks (n=283, 282, 285)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
52 weeks (n=283, 283, 285)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
SecondarySerum Calcitonin at Baseline, 52 Weeks, and 4 Weeks After Last Dose
Time frame:
Baseline and 52 weeks and 4 weeks after last dose
Reported as:
Mean · picomole per liter
Serum Calcitonin at Baseline, 52 Weeks, and 4 Weeks After Last Dose
picomole per liter1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Baseline0.75 ± 0.780.73 ± 0.770.78 ± 0.88
52 weeks (n=284, 283, 285)0.79 ± 0.890.78 ± 0.900.80 ± 0.89
4 weeks after last dose (n=245, 254, 246)0.76 ± 0.870.73 ± 0.720.87 ± 0.95
SecondaryChange From Baseline to 26 and 52 Weeks in Blood Pressure

Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline blood pressure as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · milliliters of mercury (mmHg)
Change From Baseline to 26 and 52 Weeks in Blood Pressure
milliliters of mercury (mmHg)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
SBP, 26 weeks (n=255, 261, 258)-0.97 ± 0.88-0.65 ± 0.872.23 ± 0.88
SBP, 52 weeks (n=239, 240, 246)-0.26 ± 0.941.04 ± 0.931.98 ± 0.92
DBP, 26 weeks (n=255, 261, 258)0.02 ± 0.56-0.08 ± 0.56-0.23 ± 0.56
DBP, 52 weeks (n=239, 240, 246)-0.01 ± 0.570.15 ± 0.57-0.34 ± 0.56
SecondaryBlood Pressure at Baseline, 52 Weeks, and 4 Weeks After Last Dose

Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured.

Time frame:
Baseline and 52 weeks and 4 weeks after last dose
Reported as:
Mean · milliliters of mercury (mmHg)
Blood Pressure at Baseline, 52 Weeks, and 4 Weeks After Last Dose
milliliters of mercury (mmHg)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
SBP, Baseline133.26 ± 16.56134.03 ± 15.87133.26 ± 16.97
SBP, 52 weeks (n=290, 290, 295)132.67 ± 15.40134.31 ± 16.41134.90 ± 16.25
SBP, 4 weeks after last dose (n=260, 260, 255)133.77 ± 16.80134.72 ± 16.50132.75 ± 16.01
DBP, Baseline77.33 ± 9.7377.57 ± 9.0077.18 ± 10.41
DBP, 52 weeks (n=290, 290, 295)77.33 ± 9.6377.59 ± 9.7477.07 ± 9.92
DBP, 4 weeks after last dose (n=260, 260, 255)76.58 ± 10.0677.04 ± 9.6076.94 ± 9.10
SecondaryChange From Baseline to 26 and 52 Weeks in Pulse Rate

Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline as a covariate

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline to 26 and 52 Weeks in Pulse Rate
beats per minute (bpm)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks (n=255, 261, 258)2.84 ± 0.572.79 ± 0.560.90 ± 0.56
52 weeks (n=239, 240, 246)2.38 ± 0.572.27 ± 0.570.93 ± 0.57
SecondaryPulse Rate at Baseline, 52 Weeks, and 4 Weeks After Last Dose

Seated pulse rate was measured.

Time frame:
Baseline and 52 weeks and 4 weeks after last dose
Reported as:
Mean · beats per minute (bpm)
Pulse Rate at Baseline, 52 Weeks, and 4 Weeks After Last Dose
beats per minute (bpm)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Baseline75.26 ± 11.0375.08 ± 11.1074.54 ± 10.50
52 weeks (n=290, 290, 295)78.30 ± 11.0177.83 ± 10.9076.02 ± 11.43
4 weeks after last dose (n=260, 260, 255)74.52 ± 11.0974.99 ± 11.9875.27 ± 11.17
SecondaryChange From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
milliseconds (msec)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
QTcF interval, 26 weeks (n=241, 242, 236)0.29 ± 1.130.30 ± 1.121.59 ± 1.13
QTcF interval, 52 weeks (n= 222, 221, 221)1.89 ± 1.131.48 ± 1.131.80 ± 1.14
PR interval, 26 weeks (n=238, 243, 236)0.82 ± 0.95-1.75 ± 0.94-1.13 ± 0.95
PR interval, 52 weeks (n=220, 222, 221)0.85 ± 1.000.05 ± 0.99-0.43 ± 1.00
SecondaryChange From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate

Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.

Time frame:
Baseline, 26 weeks, and 52 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate
beats per minute (bpm)1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks (n=244, 246, 243)3.95 ± 0.654.18 ± 0.651.37 ± 0.65
52 weeks (n=230, 226, 230)3.02 ± 0.673.83 ± 0.671.03 ± 0.67
SecondaryNumber of Events of Adjudicated Pancreatitis up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose

The number of adjudicated (by an independent Clinical Endpoint Committee \[CEC\]) pancreatic events is summarized at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Number · events
Number of Events of Adjudicated Pancreatitis up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
events1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeksNANANA
52 weeks000
4 weeks after last doseNANANA
SecondaryNumber of Participants With Self-reported Hypoglycemic Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose

Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose \[PG\] of ≤ 70 milligrams per deciliter \[mg/dL\]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The number of participants with self-reported hypoglycemic events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks and 52 weeks
Reported as:
Number · participants
Number of Participants With Self-reported Hypoglycemic Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
participants1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Severe HE, 26 weeks459
Severe HE, 52 weeks8714
Severe HE, 4 weeks after last doseNANANA
Documented Symptomatic HE, 26 weeks228242243
Documented Symptomatic HE, 52 weeks235250247
Documented Symptomatic HE, 4 weeks after last doseNANANA
Asymptomatic HE, 26 weeks174179198
Asymptomatic HE, 52 weeks191196207
Asymptomatic HE, 4 weeks after last doseNANANA
Total HE, 26 weeks250258264
Total HE, 52 weeks252263266
Total HE, 4 weeks after last doseNANANA
SecondaryRate of Self-reported Hypoglycemic Events up to 52 Weeks

Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose \[PG\] of ≤ 70 milligrams per deciliter \[mg/dL\]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Mean · events per participant per year
Rate of Self-reported Hypoglycemic Events up to 52 Weeks
events per participant per year1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Severe HE0.03 ± 0.190.05 ± 0.500.08 ± 0.43
Documented Symptomatic HE30.98 ± 39.6435.03 ± 44.9439.90 ± 50.92
Asymptomatic HE9.55 ± 19.5211.56 ± 24.6914.20 ± 23.19
Total HE41.52 ± 46.5147.42 ± 54.3955.93 ± 59.46
SecondaryNumber of Participants With Adjudicated Cardiovascular Events up to 52 Weeks

Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Cardiovascular Events up to 52 Weeks
participants1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
Any cardiovascular event5612
Any fatal cardiovascular event002
Any non-fatal cardiovascular event5611
SecondaryNumber of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose

A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

Time frame:
Baseline through 4 weeks after last dose
Reported as:
Number · participants
Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
participants1.5 mg or 0.75 mg LY2189265
26 weeksNA
52 weeksNA
4 weeks after last dose9
SecondaryNumber of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks, 52 weeks, and 4 weeks after last dose. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks, 52 weeks, and 4 weeks after last dose
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
participants1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
26 weeks203216178
52 weeks217230206
4 weeks after last dose223235211

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 mg LY2189265—27/295 (9.2%)219/295 (74.2%)
0.75 mg LY2189265—46/293 (15.7%)232/293 (79.2%)
Insulin Glargine—53/296 (17.9%)203/296 (68.6%)
Most frequent serious events
Showing 10 of 186
Most frequent serious events
Event1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
HypoglycemiaMetabolism and nutrition disorders6/2957/29312/296
HypoglycaemiaMetabolism and nutrition disorders3/2958/2931/296
PneumoniaInfections and infestations1/2954/2931/296
Coronary artery diseaseCardiac disorders1/2950/2933/296
MenorrhagiaReproductive system and breast disorders0/1350/1451/131
Premenopausal menorrhagiaReproductive system and breast disorders0/1350/1451/131
CholelithiasisHepatobiliary disorders0/2952/2930/296
CellulitisInfections and infestations0/2952/2931/296
GastroenteritisInfections and infestations0/2952/2930/296
Urinary tract infectionInfections and infestations0/2952/2930/296
Most frequent other events
Showing 10 of 26
Most frequent other events
Event1.5 mg LY21892650.75 mg LY2189265Insulin Glargine
NauseaGastrointestinal disorders76/29552/2939/296
DiarrheaGastrointestinal disorders44/29534/29315/296
VomitingGastrointestinal disorders35/29531/2935/296
NasopharyngitisInfections and infestations22/2951/29333/296
Common coldInfections and infestations19/29528/29326/296
HeadacheNervous system disorders16/29520/29317/296
Oedema peripheralGeneral disorders7/29517/2939/296
ArthralgiaMusculoskeletal and connective tissue disorders1/2954/29316/296
Urinary tract infectionInfections and infestations12/29514/29311/296
Pain in extremityMusculoskeletal and connective tissue disorders9/29513/2938/296

Baseline characteristics

Participants who were randomized and received at least 1 dose of LY2189265 or Insulin Glargine.

Age, Continuous
Age, Continuous(years)1.5 mg LY21892650.75 mg LY2189265Insulin GlargineTotal
Mean58.88 ± 9.5559.31 ± 8.9859.90 ± 9.0859.36 ± 9.21
Sex: Female, Male
Sex: Female, Male(Participants)1.5 mg LY21892650.75 mg LY2189265Insulin GlargineTotal
Female135145131411
Male160148165473
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1.5 mg LY21892650.75 mg LY2189265Insulin GlargineTotal
Hispanic or Latino102101100303
Not Hispanic or Latino193192196581
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.5 mg LY21892650.75 mg LY2189265Insulin GlargineTotal
American Indian or Alaska Native16131746
Asian9121435
Native Hawaiian or Other Pacific Islander0011
Black or African American32272685
White231235231697
More than one race76720
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)1.5 mg LY21892650.75 mg LY2189265Insulin GlargineTotal
United States1039596294
Taiwan89926
Greece87823
Spain810927
Russian Federation68923
Hungary19191957
Mexico19191755
Canada98926
Puerto Rico13201851
Argentina26272881
Poland13131440
Brazil33303295
Belgium55414
Denmark44412
Australia108826
Sweden11111234
Body Weight
Body Weight(kilograms (kg))1.5 mg LY21892650.75 mg LY2189265Insulin GlargineTotal
Mean91.00 ± 18.2491.69 ± 18.0390.75 ± 18.8791.14 ± 18.37
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m^2))1.5 mg LY21892650.75 mg LY2189265Insulin GlargineTotal
Mean31.99 ± 5.1133.08 ± 5.1532.41 ± 5.3332.49 ± 5.21
Glycosylated Hemoglobin (HbA1c)
Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin)1.5 mg LY21892650.75 mg LY2189265Insulin GlargineTotal
Mean8.46 ± 1.088.40 ± 1.038.53 ± 1.038.46 ± 1.05

1 further baseline measures are reported on the registry.

08

Study locations

101 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Concord, California 94520, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Mesa, California 91942, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lancaster, California 93534, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Britain, Connecticut 06050, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hollywood, Florida 33021, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32209, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winter Haven, Florida 33880, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii 96813, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lexington, Kentucky 40503, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paducah, Kentucky 42003, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Metairie, Louisiana 70006, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Orleans, Louisiana 70121, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haverhill, Massachusetts 01830, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Massachusetts 01199, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Waltham, Massachusetts 02453, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Worcester, Massachusetts 01605, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Minneapolis, Minnesota 55416, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chesterfield, Missouri 63017, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashua, New Hampshire 03063, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toms River, New Jersey 08753, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albany, New York 12206, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Asheville, North Carolina 28803, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Morehead City, North Carolina 28557, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fargo, North Dakota 58103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Eugene, Oregon 97401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Myrtle Beach, South Carolina 29572, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38119, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78731, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Federal Way, Washington 98003, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Renton, Washington 98057, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, Washington 98664, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wenatchee, Washington 98801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1034ACO, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cipolletti, 8324, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mendoza, M5500CCE, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salta, 4406, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Keswick, South Australia 5035, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Box Hill, Victoria 3128, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Melbourne, Victoria 3004, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bonheiden, 2820, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, 1070, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Genk, 3600, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liège, 4000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Belem, 66073-000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fortaleza, 60430-350, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Porto Alegre, 90035-170, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 04266-010, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Westminster, British Columbia V3L 3W5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winnipeg, Manitoba R3E 3P4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Ontario N6G 4X8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gatineau, Quebec J8V 2P5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sherbrooke, Quebec J1G 5K2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aarhus, 8000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hillerod, Dk-3400, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kobenhavn, 2400, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Koege, 4600, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kolding, 6000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ampelokipoi, 11527, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, 11527, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nikaias - Piraeus, 18454, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Thessaloniki, 54639, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bekescsaba, 5600, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1115, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gyongyos, 3200, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miskolc, 3529, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagykanizsa, 8800, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nyiregyhaza, 4400, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Papa, 8500, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Culiacan, 80020, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44650, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Merida, 97070, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64461, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdynia, 81-557, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-242, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Radzymin, 05-250, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 50-349, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manati, 00674, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ponce, 00728, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00917-3104, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yabucoa, 00767, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 127486, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Petersburg, 191126, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Samara, 443095, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08022, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28046, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palma De Mallorca, 07010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pozuelo De Alarcon, 28223, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Teruel, 44002, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46014, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Karlstad, 65185, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lund, 22185, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stockholm, 113 61, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaohsiung, 807, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sindian City, 23148, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 404, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 11031, Taiwan

Showing the first 100 of 101 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pantalone KM, Patel H, Yu M, Fernandez Lando L. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Diabetes Obes Metab. 2018 Jun;20(6):1461-1469. doi: 10.1111/dom.13252. Epub 2018 Mar 23. PubMed 29430801 ↗
  • Boustani MA, Pittman I 4th, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016 Aug;18(8):820-8. doi: 10.1111/dom.12687. Epub 2016 Jun 7. PubMed 27161178 ↗
  • Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016 Apr;18(4):419-24. doi: 10.1111/dom.12624. Epub 2016 Feb 4. PubMed 26691396 ↗
  • Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015 May 23;385(9982):2057-66. doi: 10.1016/S0140-6736(15)60936-9. PubMed 26009229 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Feb 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 8 months after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2010
First posted
Aug 30, 2010
Start
Nov 2010
Primary completionActual
Feb 2012
CompletionActual
Sep 2012
Results delay requested
May 24, 2012
Results first posted
Oct 8, 2014
Last update
Oct 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01191268
Responsible party
Sponsor
First posted
Aug 30, 2010
Start date
Nov 2010
Primary completion
Feb 2012
Completion
Sep 2012
Results posted
Oct 8, 2014
Last update
Oct 8, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion